Literature DB >> 18534699

Response to "Future costs and the future of cost-effectiveness analysis".

David Meltzer1.   

Abstract

Mesh：

Year:  2008        PMID： 18534699     DOI： 10.1016/j.jhealeco.2008.05.001

Source DB:  PubMed          Journal:  J Health Econ        ISSN： 0167-6296            Impact factor:   3.883


× No keyword cloud information.
  6 in total

1.  Standardizing the inclusion of indirect medical costs in economic evaluations.

Authors:  Pieter H M van Baal; Albert Wong; Laurentius C J Slobbe; Johan J Polder; Werner B F Brouwer; G Ardine de Wit
Journal:  Pharmacoeconomics       Date:  2011-03       Impact factor: 4.981

Review 2.  Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions?

Authors:  David R Rappange; Pieter H M van Baal; N Job A van Exel; Talitha L Feenstra; Frans F H Rutten; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

3.  Pharmacoeconomic guidelines should prescribe inclusion of indirect medical costs! A response to Grima et Al.

Authors:  Pieter van Baal; David Meltzer; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2013-05       Impact factor: 4.981

4.  Future costs in cost-effectiveness analysis: an empirical assessment.

Authors:  Marie Kruse; Jan Sørensen; Dorte Gyrd-Hansen
Journal:  Eur J Health Econ       Date:  2010-09-28

5.  Cost-effectiveness of pharmacotherapy to reduce obesity.

Authors:  J Lennert Veerman; Jan J Barendregt; Megan Forster; Theo Vos
Journal:  PLoS One       Date:  2011-10-27       Impact factor: 3.240

6.  Future Costs in Cost-Effectiveness Analyses: Past, Present, Future.

Authors:  Linda M de Vries; Pieter H M van Baal; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2019-02       Impact factor: 4.981
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.